Physician profile
Laura Moore
NPI 1366113474
$2,485.26
in general payments reported to CMS, 2019-2025
41 companies · $1,338 in 2025
The $1,338 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.35 · 2022: $215 · 2023: $215 · 2024: $706 · 2025: $1,338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,259.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $195.42 | 2021-2025 | Imfinzi, Enhertu |
| Janssen Biotech, INC. | $172.84 | 2024-2025 | Erleada, Akeega, Tecvayli |
| Novartis Pharmaceuticals Corporation | $165.36 | 2024-2025 | |
| Pfizer INC. | $140.97 | 2022-2025 | |
| Lilly USA, LLC | $128.25 | 2023 | Retevmo |
| Biohaven Pharmaceutical Holding Company LTD. | $121.17 | 2022 | |
| Genentech USA, INC. | $116.96 | 2024-2025 | Tecentriq, Kadcyla, Phesgo |
| Abbvie INC. | $94.63 | 2025 | |
| Daiichi Sankyo INC. | $86.96 | 2024-2025 | Enhertu, Injectafer |
| Glaxosmithkline, LLC. | $84.46 | 2024-2025 | Ojjaara, Jemperli |
| Bayer Healthcare Pharmaceuticals INC. | $81.03 | 2025 | |
| Genmab U.S., INC. | $78.99 | 2023-2025 | Tivdak, Epkinly |
| Incyte Corporation | $70.58 | 2025 | Jakafi, Niktimvo, Zynyz |
| Tersera Therapeutics LLC | $61.41 | 2024-2025 | Zoladex |
| Caris Mpi, INC. | $56.35 | 2025 | Mi Cancer Seek |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.